Objective. Gout is the most common form of inflammatory arthritis and is caused by hyperuricaemia. Some studies have found a reduction in plasma urate with vitamin C supplementation. We tested the hypothesis that high plasma vitamin C is causally associated with low plasma urate and low risk of hyperuricaemia, using a Mendelian randomization approach.
Introduction
Gout is the most common form of inflammatory arthritis [1] and is caused by chronically elevated urate levels (hyperuricaemia) [2] . Epidemiological studies have shown an inverse association between plasma vitamin C and plasma urate [3] , as well as between intake of vitamin C and plasma urate [4] , risk of gout and inflammatory polyarthritis [5, 6] . This has been substantiated by a meta-analysis, which found reduction in plasma urate with vitamin C supplementation [7] . Although these findings suggest a role for vitamin C in the prevention and management of uraterelated diseases, other studies have found no effect of vitamin C on plasma urate [8, 9] . We here apply a different approach to the question of a urate-lowering effect of vitamin C, the Mendelian randomization design [10, 11] . Mendelian randomization refers to the random assortment of genes at the time of gamete formation, which allows for a genetic variant to be used to study risk of disease, largely free of confounding and reverse causation [10] . We use the rs33972313 variation in the SLC23A1 gene, encoding the sodium-dependent vitamin C transporter 1 (SVCT1) associated with changes in plasma vitamin C levels [12, 13] and the rs7442295 variation in the SLC2A9 gene, encoding the high-capacity urate transporter GLUT9, associated with changes in plasma urate levels [14, 15] , to assess the consequences of genetically determined high plasma vitamin C on urate and vice versa. This allows us to largely circumvent confounding (as genotypes are randomly distributed) and reverse causation (as a genotype cannot be altered by disease), problems otherwise inherent in observational studies.
In the present study, we tested the hypothesis that high plasma vitamin C is causally associated with low plasma urate. First, we measured plasma vitamin C in 9234 individuals and plasma urate in 106 147 individuals. Second, we genotyped for the SLC23A1 rs33972313 variant associated with plasma vitamin C and performed instrumental variable analyses with urate levels as an outcome. Third, to assess the direction of causality in the relationship between vitamin C and urate, we genotyped for the SLC2A9 rs7442295 variant, in order to test whether high plasma urate is causally associated with low plasma vitamin C. Figure 1 outlines the study design.
Methods

Study population
We used the Copenhagen General Population Study (CGPS), initiated in 2003 with ongoing enrolment [16] . Individuals aged 20100 years were invited randomly from the Danish Civil Registration System to complete a questionnaire, undergo a physical examination and give blood for plasma measurements and DNA analyses. The study was approved by Herlev and Gentofte Hospital and Danish Ethical Committees, conducted according to the Declaration of Helsinki and written informed consent was obtained from all participants. We only included white individuals of Danish descent with DNA available, giving a total of 9234 with plasma vitamin C measurements, and 106 147 individuals with plasma urate measurements, all genotyped for the SLC23A1 rs33972313 vitamin C variation. A total of 9111 had both plasma urate and vitamin C measurements done. The numbers of individuals with each biomarker measured differ as plasma urate had 
Covariates
Information on smoking, alcohol intake, physical activity and income, use of vitamin supplements and diuretics, and intake of fruit, vegetables and beef was self-reported. Cumulative tobacco consumption was calculated from questionnaire information and reported in pack-years; one pack-year was 20 cigarettes or equivalent smoked per day for 1 year. Systolic blood pressure was measured. BMI was calculated from measured weight in kilograms divided by measured height in metres squared. Hyperuricaemia was defined as plasma urate >360 mmol/l for both men and women. In sensitivity analyses, to take into account the large difference in urate levels between men and women, we defined hyperuricaemia as plasma urate >360 mmol/l for women and >420 mmol/l for men, as most often defined [17] .
Laboratory analyses
We genotyped for the rs7442295 in the SLC2A9 gene, encoding GLUT9 (a high-capacity urate transporter) [14] , and the rs33972313 in the SLC23A1 gene, encoding the SVCT1 [12, 13] , using TaqMan-based assays (Applied Biosystems, CA, USA) and Taqman GenoTyper v1.2. We used DNA extracted from leucocytes in peripheral blood using the Qiagen blood kit (Hilden, Germany) for DNA extraction. Genotypes were assigned in smaller batches, each batch containing around 5500 individuals with call rates of 99.299.8%. Plasma urate was measured using Konelab autoanalyser and a standard Konelab assay as supplied by the manufacturer (Thermo Fischer Scientific Inc., MA, USA) was used, which includes incubation of the sample with ascorbate oxidase to eliminate interference caused by ascorbic acid [18] . For the assay, the
FIG. 1 Study design
Step 1: Association between plasma vitamin C and plasma urate.
Step 2: Association between SLC23A1 rs33972313 and plasma vitamin C and association between SLC2A9 rs7442295 and plasma urate.
Step 3: Association between SLC23A1 rs33972313 and plasma urate and association between SLC2A9 rs7442295 and plasma vitamin C.
Step 4: Instrumental variable analysis of genetically determined plasma vitamin C on plasma urate. Dotted line: association may be confounded.
cumulative coefficient of variation was 4.3%, lower limit of detection 5 mmol/l and the measurement range 101200 mmol/l. Vitamin C had been measured consecutively since 2013 using a fluorometric assay (BioAssay Systems, CA, USA) as previously described [19] , and included 9234 measurements at the time of analyses. Plasma concentrations of high-sensitive CRP and creatinine were measured with standard hospital assays.
Statistical analyses
We used Stata v.13.1. A chi-square test evaluated HardyWeinberg equilibrium. P-values for trends were estimated using Cuzick's non-parametric trend test and KruskalWallis test was used when comparing two samples. All reported P-values were two-sided. The data was >98% complete and missing values for covariates were imputed according to age and sex for multivariable adjustment to obtain a complete dataset; however, if individuals with any missing data were excluded, results were similar to those presented.
First, to test whether plasma vitamin C was associated with plasma urate, heteroscedasticity robust linear regressions were used. We adjusted either for sex and age, or multivariable for factors potentially influencing levels of urate and vitamin C, that is, for age, BMI, alcohol intake, systolic blood pressure, intake of beef, plasma CRP as continuous variables and sex, smoking status (never smoker, former smoker and or current smoker), fruit and vegetable intake (high, medium or low intake), income (in six groups), physical activity during leisure time (in four groups), any use of vitamins and diuretics (yes/no) and quintiles of plasma creatinine as categorical variables. Furthermore, we adjusted for lot number or year and month of blood sampling to account for lot-to-lot variation in laboratory analyses. The assumption of linearity was tested visually using a plot of observed vs predicted values. We tested for homoscedasticity visually using a plot of residuals vs predicted values, and for normality of residuals by plotting residuals vs predicted values or the X-variable. No major violations to linearity, homoscedasticity or normality were observed. We investigated potential interactions of plasma vitamin C and vitamin C genotype with sex, creatinine above vs within the reference interval (as a proxy for renal function) and hyperuricaemia on plasma urate levels using a likelihood ratio test by introducing a two-factor interaction term in a model also including both factors.
Second, to test whether the two genotypes were associated with plasma vitamin C and urate, we performed linear regression adjusted for sex and age. First, we performed a linear regression of log-transformed vitamin C on the vitamin C and the urate genotype, respectively, followed by exponentiation of the b-coefficient to obtain a per allele change in plasma vitamin C expressed in percent. Second, we performed a linear regression of logtransformed urate on the vitamin C and the urate genotype, respectively, similarly exponentiating the beta coefficient to obtain a per allele change expressed in percent. In these analyses, for the vitamin C rs33972313 variant, we combined AA homozygotes and AG heterozygotes as the reference group in order to maximize statistical power. The strength of a genotype as an instrument were assessed by the F-statistic, where F > 10 indicates sufficient strength to carry out statistically reliable instrumental variable analyses [10] , and by R 2 as a measure of variation explained by genotype. Third, to assess the association between high plasma vitamin C and the risk of hyperuricaemia, we performed logistic regression adjusted for sex and age or multivariable adjusted as described above. Additionally, we performed instrumental variable analyses using the Wald-type estimator, which involves taking the ratio of the outcome-allele score coefficient (the hyperuricaemia-allele score log odds ratio from regression on 106 147 individuals from the CGPS) to the exposure-allele score coefficient (the coefficient from the regression of plasma vitamin C on SLC23A1 rs33972313 genotype on 9234 individuals from CGPS), and then exponentiating to express an odds ratio, with standard errors derived using the delta method [20] . Furthermore, in order to validate our findings, we performed two-sample instrumental variable analyses as described above, only the exposure-allele score coefficient was derived from the literature (from regression on approximately 15 000 individuals from five different cohorts with plasma vitamin C measurements available) instead of from our own sample [13, 21, 22] . As a sensitivity analysis, we performed two-sample instrumental variable analyses using an exposure-allele score coefficient derived from a meta-analysis of our own estimate and estimates of five other studies of the association between plasma vitamin C and rs33972313 [the CGPS (n = 9234), British Women's Heart and Health Study (BWHHS) (n = 3425), British Regional Heart Study (BRHS) (n = 3740), 10 Towns (n = 1359), European Prospective Investigation into Cancer and Nutrition Norfolk Study -Norfolk (EPIC) (n = 4501) and MIDSPAN (n = 1814), combined using the metan function [13] ].
Results
Plasma vitamin C and plasma urate were associated with most potential confounders (see supplementary Table S1 available at Rheumatology online). In contrast, potential confounders were equally distributed between the SLC23A1 vitamin C genotypes and the SLC2A9 urate genotypes (see supplementary Table S1 available at Rheumatology online), illustrating that the genotypes can be used as largely unconfounded instruments of plasma vitamin C and urate, respectively. Genotype distributions are presented in Table 1 .
Plasma levels of vitamin C and urate: observational association High plasma vitamin C was associated with low plasma urate (P for trend = 4 Â 10 À51 ) ( Table 1) . In a linear regression adjusted for sex and age, each 10 mmol/l higher plasma vitamin C was associated with À8.2 mmol/l (95% CI: À6.5 to À9.9) lower plasma urate (Fig. 2) . In the https://academic.oup.com/rheumatology multivariable adjusted model each 10 mmol/l higher plasma vitamin C was associated with a À2.3 (À0.69 to À3.9) mmol/l lower plasma urate.
Genotypes and plasma vitamin C and urate Plasma vitamin C was associated with the SLC23A1 rs33972313 variant with a 3.1 mmol/l (95% CI: 2.4, 3.9) higher plasma vitamin C concentration in GG homozygotes compared with AA homozygotes and AG heterozygotes combined, corresponding to 9% (95% CI: 5.6, 11.9) higher plasma vitamin C (Fig. 3) , with an F-value of 70 and an R 2 of 0.7%. The SLC2A9 rs7442295 variant was associated with 34 mmol/l (95% CI: 32, 36) higher plasma urate in GA heterozygotes, and 54 mmol/l (95% CI: 52, 56) higher plasma urate in AA homozygotes compared with GG homozygotes, corresponding to 15% (95% CI: 14%, 16%) and 23% (95% CI: 22%, 24%) higher plasma urate, respectively, with an F-value of 2443 and an R 2 of 2%. The urate SLC2A9 variant was not associated with plasma vitamin C (P for trend = 0.98), nor was the SLC23A1 vitamin C variant associated with plasma urate (P = 0.31) (Fig. 3) .
Plasma vitamin C and hyperuricaemia: observational and genetic analyses
Among the 106 147 individuals with plasma urate available, a total of 24 099 (23%) had hyperuricaemia with a higher prevalence in men (40%) than in women (9%). The odds ratios for hyperuricaemia were step-wise lower with increasing plasma vitamin C tertiles, with an odds ratio of 0.84 (0.72, 0.98) for the highest vitamin C tertile compared with the lowest tertile after multivariable adjustments (P for trend over three groups = 0.03) (Fig. 4) . For each 10 mmol/l higher plasma vitamin C, the odds ratios for hyperuricaemia were 0.80 (95% CI: 0.75, 0.84) after age and sex adjustments, and 0.92 (0.86, 0.98) after multivariable adjustments. In contrast, the SLC23A1 genotype, which 
FIG. 2 Association between plasma vitamin C and plasma urate
Estimates are from linear regression with robust standard errors to account for heteroscedasticity. Grey area is the 95% CI for the regression line. Multivariable adjusted was for age, BMI, alcohol intake, systolic blood pressure, intake of beef, plasma CRP as continuous variables and sex, smoking status (never smoker, former smoker and or current smoker), fruit and vegetable intake (high, medium or low intake), income (in six groups), physical activity during leisure time (in four groups), any use of vitamins and diuretics (yes/no) and quintiles of plasma creatinine as categorical variables, as well as lot number or year and month of blood sampling.
was associated with a 9% higher plasma vitamin C in GG homozygotes, gave an odds ratio of 1.03 (0.96, 1.10) for hyperuricaemia for GG vs AG + AA (data not shown).
Further, a genetically determined 10 mmol/l higher plasma vitamin C was associated with an odds ratio of 1.01 (0.84, 1.23) for hyperuricaemia with a corresponding two-sample instrumental variable analysis odds ratio of 1.01 (0.92, 1.11) (Fig. 4) .
FIG. 3 Vitamin C and urate genotypes and the association with plasma vitamin C and urate, respectively
Mean and 95% CI from linear regression adjusted for sex and age. P for trend is from Cuzick's non-parametric trend test. P is from Kruskal-Wallis test.
FIG. 4 Observational and genetic estimates of the association between plasma vitamin C and hyperuricaemia
Hyperuricaemia was defined as plasma urate >360mmol/l for both men and women. In the two-sample instrumental variable analysis, the gene-exposure estimate is from a meta-analysis by Timpson et al. [13] , and the gene-outcome estimate is from the Copenhagen General Population Study. Multivariable adjusted was for sex, age, smoking status, alcohol intake, fruit and vegetable intake, intake of beef, income, physical activity during leisure time, BMI, systolic blood pressure, any use of vitamins, plasma creatinine and plasma CRP. Genetic estimate was adjusted for sex and age. OR: odds ratio.
Sensitivity analyses
In our pre-specified interaction analyses, no significant interactions were found for plasma vitamin C or SLC23A1 rs33972313 with sex, renal function or hyperuricaemia on plasma urate (all P > 0.30) (see supplementary Fig. S2 available at Rheumatology online). For the SLC2A9 rs7442295 urate variant, we found a well-known interaction with sex with regard to plasma urate (P for interaction < 0.001) [15] , but not to plasma vitamin C levels (P for interaction = 0.54).
In order to incorporate available information on the SLC23A1 rs33972313-plasma vitamin C association, we performed a two-sample instrumental variable analysis of the association between genetically high plasma vitamin C and hyperuricaemia, using the exposure-gene coefficient from our own estimate combined in a meta-analysis with five other studies of the rs33972313-plasma vitamin C association. This allowed us to include the exposure-gene association from approximately 24 000 individuals, and we found results very similar to those from the Copenhagen General Population Study alone (see supplementary Figs S3 and S4 Rheumatology online). Furthermore, analyses of hyperuricaemia defined using sex-specific cut-offs (>360 mmol/l for women and >420 mmol/l for men) gave similar results as the uniform cut-off of >360 mmol/l (see supplementary Fig. S5 available at Rheumatology online).
Discussion
We used an observational design as well as a Mendelian randomization design in 106 147 individuals to explore the relationship between plasma vitamin C and urate. Observationally, we found high plasma vitamin C to be associated with low plasma urate and with lower risk of hyperuricaemia, findings that remained, although much attenuated, after multivariable adjustments. However, in the Mendelian randomization study the SLC23A1 genetic variant, associated with 9% higher plasma vitamin C and none of the confounders of the plasma vitamin C-urate association, was not associated with plasma urate levels or with lower risk of hyperuricaemia. Thus, our data do not support a causal relationship between high plasma vitamin C and low urate. Although we cannot completely exclude a very small effect of vitamin C on urate, we speculate that the remaining small observational association between vitamin C and urate after adjustment for likely confounders is caused by residual confounding [23] .
Previously, observational studies have shown a negative correlation between plasma vitamin C and urate levels [3] , risk of hyperuricaemia [4] as well as between higher intake of vitamin C and risk of gout [5] , although with conflicting findings in some studies [24] . Several intervention trials have been carried out in order to assess the effect of vitamin C on urate levels. A meta-analysis of 13 randomized controlled trials (n = 556) found a reduction in plasma urate of À20.8 mmol/l with vitamin C supplementation (median intake 500 mg/day), but the included trials were small, of variable design quality and heterogeneity between trials was significant [7] . In contrast, one recent randomized controlled trial of the effect of vitamin C in lowering plasma urate in gout patients (n = 40) alone or in addition to allopurinol treatment found no change in urate levels after 8 weeks of vitamin C supplementation alone (500 mg/day) nor with vitamin C supplementation in addition to allopurinol treatment [9] . Possibly, these conflicting findings could indicate a modification of the effect of vitamin C by urate levels, however, we found no evidence that the effect of plasma vitamin C or genetically high vitamin C on plasma urate should differ among normouricaemic and hyperuricaemic individuals. Thus, even if a urate-lowering effect of vitamin C does exist, our results suggest it to be very modest at best and high vitamin C does not seem to achieve a lowering of urate to an extent, relevant for prevention and management of urate-related disorders. Plasma vitamin C has previously been associated with cardiometabolic traits with little genetic support for these associations [19, 25] ; similarly, in our study of plasma vitamin C and urate the observational association with vitamin C is not replicated in genetic studies. Thus, our study of plasma vitamin C and urate extends the number of phenotypes for which the observational association with vitamin C does not seem to be causal.
Our study is the largest study to date to examine the observational associations and the first study to apply the Mendelian randomization design to the question of an effect of vitamin C on urate in a general population. The SLC23A1 rs33972313 seems like a valid instrument for this, as it is robustly associated with vitamin C, the gene encodes the SVCT1 involved in renal and intestinal vitamin C uptake and likely only asserts an effect through plasma vitamin C. Finally, we show that it is not associated with any of the potential confounders of the plasma vitamin C-urate association. Other strengths of this study include a large sample size from a homogeneous general population and adjustment for a large number of potential confounders. However, some limitations should be considered. First, the genetic estimate of the effect of vitamin C is based on a single and uncommon genetic variant that only explains 0.7% of the variation in plasma vitamin C, and thus limits our ability to draw firm conclusions. Stronger genetic instruments for plasma vitamin C may be desired in order to increase statistical power; however, the rs33972313 is the strongest genetic instrument for plasma vitamin C concentrations identified at this time [13] . Second, plasma levels of vitamin C may not be the sole determinant of vitamin C function; diet or genetic variants such as in SLC23A2, encoding the transporter SVCT2 responsible for vitamin C uptake into metabolically active tissue [26] , could attenuate any effect of genetically determined high plasma vitamin C on plasma urate levels. Additionally, a limitation such as developmental compensation may be considered. Possibly, the presence of the high vitamin C genotype in fetal or early post-natal life may lead to permanent changes in tissue structure and function that could counterbalance the effect of high vitamin C without altering the association between genotype and vitamin C [10] . Third, we only measured plasma vitamin C in a subgroup (n = 9345 measured since 2013) of the most recently recruited CGPS participants; however, we found no evidence that this group differed from the remaining CGPS. Fourth, all participants were of Danish descent, thus our results may not necessarily apply to other races, yet, we are not aware of data to suggest that the present results should not be applicable to most ethnic groups; however, this minimizes the risk of population stratification affecting instrumental variable analyses.
In conclusion, we found that high plasma vitamin C was associated with low plasma urate and with low risk of hyperuricaemia, although much attenuated after multivariable adjustments. However, the SLC23A1 genetic variant, which was associated with 9% higher plasma vitamin C and with none of the possible confounders of the plasma vitamin C-urate association, was not associated with plasma urate levels or with low risk of hyperuricaemia. Thus, our data do not support a causal relationship between high plasma vitamin C and low urate. 
